Intas is a leading, vertically integrated global pharmaceutical formulation development, manufacturing and marketing company headquartered in India.
Intas' success and incessant growth lies in clinical execution of successful and strategic moves made in the areas of manufacturing, R & D, Biotechnology and global operations over three decades. Intas is now ranked as the 10th largest pharmaceutical company in the domestic market (as per OCT-16 IMS SSA & TSA datasets).
In the domestic market, Intas is the 4th largest corporate in Indian Chronic Pharma Market with a market share of more than 5.33%. It also has presence in central nervous system (CNS), cardiovascular system (CVS), diabetology, and gastroenterology and pain management. Recently, Intas has extended its presence into other therapy areas such as gynecology, infertility and respiratory care.
Besides rapidly growing domestic prominence, Intas is also present in more than 70 countries worldwide with robust sales, marketing and distribution infrastructure in markets like North America, Europe, Central & Latin America, Africa, Australia, New Zealand, and Asia - Pacific as well as CIS and MENA countries.
Intas' global strategy includes alliances with leading Global Pharma Companies for development and distribution of products as well as direct product distribution.
Intas has made a substantial commitment to its Biologics Business Unit in terms of creating R&D, manufacturing and marketing capabilities for its biotech portfolio. Continual R & D initiatives have strengthened niche and complex product offerings in India and International markets. Commercialized in India, three pharmaceutical formulations are based on the novel lipid based drug delivery system with studies ongoing to extend these products to International markets.
Intas has made strategic investments in ten manufacturing facilities, globally. Between them, these facilities have received approvals from various prominent international regulatory bodies, including U.S. Food and Drug Administration (FDA).
Recently, Intas added another feather in its basket afteragreements to acquire Actavis UK Ltd. & Actavis Ireland Ltd. (“Actavis UK & Ireland”) from Teva Pharmaceutical Industries Ltd. (“Teva”) for an enterprise value of approximately £600 million.